Background
• Pharmacogenetic information is accumulating rapidly and is beginning to show consistent reproducible results for an increasing number of genetic markers for drug response.
• Several consortia have published guidelines to aid physicians and pharmacists with the interpretation and clinical translation of pharmacogenetic test results.
• An increasing number of medical centers have acquired clinical genotyping facilities.
• Among the first medical centers to implement pharmacogenetics there are many highly specialized care centers with complex patient populations.
• These patients may present some unexpected challenges as is exemplified by the following case description. 
Case
• Female patient, 20 years old.
• Admitted to the LUMC for living related kidney transplantation.
• Adequate tacrolimus exposure early after transplantation is essential.
• Prior to kidney transplantation, patient is preemptively genotyped for CYP3A5*3 (rs776746) and CYP3A5*6 (rs10264272).
• Genotyping: in duplicate by two independent techniques, to mimimize the risk of potential errors.
• Genotyping results from Pyrosequencing and Taqman were conflicting.
• Pyrosequencing  CYP3A5*1/*3 • TaqMan  CYP3A5*3/*3 • Further research: second blood sample and consulting the nephrologist
Tacrolimus and kidney transplantation
• Patients receive standard quadruple immunosuppressive regime: basiliximab, tacrolimus, mycophenolate, prednisolone.
• Tacrolimus is metabolized into active and inactive metabolites by CYP3A4 and CYP3A5.
• Patients carrying at least one copy of the CYP3A5*1 allele require a significantly increased tacrolimus dose to attain therapeutic blood concentrations.
 All patients undergoing a kidney transplantation in the LUMC from 2009 onward are preemptively genotyped for the CYP3A5*3 (rs776746) and CYP3A5*6 (rs10264272) polymorphisms 
Results Case
• 1992: 1 st allogeneic stem cell transplantation to treat beta-thalassemia major. Transplant rejected.
• 2009: 2 nd allo-SCT from a second donor. Result is a mixed hematopoietic chimerism (28% autologous, 72% donor).
• Saliva samples from patient and donor were collected and genotyped for the CYP3A5*3 and CYP3A5*6.
• The donor was autocalled CYP3A5*3/*3 • The patient was autocalled CYP3A5*1/*3.
• This genotype is in line with the relatively low tacrolimus trough level (5.5 ug/L).
• AUC levels of 110 µg*hours/L were achieved with a tacrolimus dose of 8 mg twice daily. 
Discussion
• This case illustrates  The challenging aspects of pharmacogenetic testing  The importance of proper quality control mechanisms  Selection of the proper source of DNA to determine the genotype in Tx patients • To determine germline DNA in SCT patients: buccal swabs should be used.
• Pharmacogenetic testing in solid organ transplantation recipients should be handled with great care.
• Taking the transplant type, the metabolic pathway, mechanism of action and toxicity of the applied drugs into consideration.
